Allinky Biopharma

Among the therapeutic areas of partnering interest, for the top pharmaceutical companies, oncology, inflammation and CNS are the highest ranked. The market value for these indications exceeds any calculation and many approaches are being developed to gain a small percentage of such value. Unfortunately straight forward approaches to target proteins driving cancer or inflammatory diseases are not always feasible. Important protein targets in theses diseases are undrugable through their active site, often due to off-target effects. Indeed, drugs that bind to the active site of target proteins might mimic the structure of energy substrates – for example when the protein’s active site harbors systemic energy substrates such as ATP and GTP. Accordingly, such drugs might switch off other proteins that are important for the activity of specific cells in the body. By contrast, allosteric sites are highly specific to a given protein target and in fact, nature employs these sites to selectively modulate given proteins. Allinky has developed its own proprietary technology platform to identify allosteric sites in protein targets, and to thereafter develop allosteric compounds (small molecules) with therapeutic properties. Indeed, some top-selling drugs in the market are allosteric compounds. Allinky is currently advancing drug development programs focused on two families of innovative proprietary small molecules (allosteric inhibitors): AIK3 and AIK4. These therapeutic molecules are being developed to treat inflammatory diseases like COPD (chronic obstructive pulmonary disease) and AMD (age-related macular degeneration) as well as cancer driven by the Ras family of proto-oncogenes that are found in certain types of lung, colorectal and pancreatic cancer as well as lymphomas.